Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Jul 24, 2017 Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection) Jul 12, 2017 Theratechnologies Announces Financial Results For The Second Quarter Of 2017 Jul 05, 2017 Theratechnologies To Announce Financial Results For The Second Quarter Of 2017 Jun 30, 2017 FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab May 16, 2017 Announcements in Conjunction With Theratechnologies Annual Meeting May 16, 2017 Shareholders Elect New Board Member During Theratechnologies’ Annual Meeting May 03, 2017 Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab Apr 06, 2017 Theratechnologies Announces Financial Results for First Quarter of 2017 Mar 30, 2017 Theratechnologies to Announce Financial Results for the First Quarter of 2017 Mar 06, 2017 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories First page « Previous page ‹ … Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Page 33 … Next page › Last page » Displaying 281 - 290 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Jul 24, 2017 Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)
Jun 30, 2017 FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
May 03, 2017 Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Mar 06, 2017 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories
